{"id":"esketamine-dpi-low-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Dissociation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2364609","moleculeType":"Small molecule","molecularWeight":"274.19"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Esketamine is the S-enantiomer of ketamine, which acts as a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor. The dry powder inhaled (DPI) formulation allows for rapid systemic absorption and CNS penetration. This mechanism is thought to promote synaptic plasticity and neuronal growth, leading to faster antidepressant effects compared to traditional monoamine-based antidepressants.","oneSentence":"Esketamine is an NMDA receptor antagonist that blocks glutamate signaling in the brain, with rapid-acting antidepressant effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:59:46.179Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment-resistant depression (Phase 2 investigation)"},{"name":"Major depressive disorder with suicidal ideation (potential indication)"}]},"trialDetails":[{"nctId":"NCT03965871","phase":"PHASE2","title":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression","status":"COMPLETED","sponsor":"Celon Pharma SA","startDate":"2019-03-28","conditions":"Bipolar Depression","enrollment":88},{"nctId":"NCT03965858","phase":"PHASE2","title":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression","status":"COMPLETED","sponsor":"Celon Pharma SA","startDate":"2019-02-25","conditions":"Major Depressive Disorder","enrollment":88},{"nctId":"NCT03407872","phase":"PHASE1","title":"Safety and Pharmacokinetic Study of Inhaled Esketamine in Healthy Volunteers","status":"COMPLETED","sponsor":"Celon Pharma SA","startDate":"2017-12-09","conditions":"Healthy Volunteers","enrollment":63}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Esketamine DPI - low dose","genericName":"Esketamine DPI - low dose","companyName":"Celon Pharma SA","companyId":"celon-pharma-sa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Esketamine is an NMDA receptor antagonist that blocks glutamate signaling in the brain, with rapid-acting antidepressant effects. Used for Treatment-resistant depression (Phase 2 investigation), Major depressive disorder with suicidal ideation (potential indication).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}